Finalist
Maloff Protect Reclassification & Launch
Summary of work
Hamell worked with Glenmark Pharmaceutical on the successful prescription-only to pharmacy (POM-to-P) ‘Switch’ of Maloff Protect (atovaquone/proguanil), used as chemoprophylaxis for malaria. Over the last 15 years, we have worked on many of the complex Switches in the UK and Europe, and know that with any Switch the balance of power shifts from prescribers (GPs/specialists) to pharmacists and consumers themselves. In order to change pharmacist and consumer behaviours for Maloff Protect, we must first take a robust and evidence-based approach in trying to understand them. To do this, we conducted behavioural research in-pharmacy and with consumers in the UK. We also utilised insights from our self-funded study involving over 750 pharmacists from across Europe. These research findings directly underpinned every element of Maloff Protect’s Switch and launch, allowing us to disseminate tailored content that evoked real and tangible changes in behaviours.
Judges’ comments
Glenmark Pharmaceutical and Hamell demonstrated a really good use of insight research to shape a communications programme with strong results. They showed an interesting approach to market research with strong result.
